JP2023524912A - ４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用 - Google Patents

４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用 Download PDF

Info

Publication number
JP2023524912A
JP2023524912A JP2023509462A JP2023509462A JP2023524912A JP 2023524912 A JP2023524912 A JP 2023524912A JP 2023509462 A JP2023509462 A JP 2023509462A JP 2023509462 A JP2023509462 A JP 2023509462A JP 2023524912 A JP2023524912 A JP 2023524912A
Authority
JP
Japan
Prior art keywords
effective amount
days
administration
administering
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524912A5 (enExample
Inventor
マーク ジェイ スト
レベッカ ブーヘイカー
ドゥ ヨン チョン
ジン ス リ
ヒョニョン チョ
Original Assignee
サウザーン リサーチ インスチチュート
ピノットバイオ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サウザーン リサーチ インスチチュート, ピノットバイオ，インコーポレイテッド filed Critical サウザーン リサーチ インスチチュート
Publication of JP2023524912A publication Critical patent/JP2023524912A/ja
Publication of JP2023524912A5 publication Critical patent/JP2023524912A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023509462A 2020-04-23 2021-04-22 ４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用 Pending JP2023524912A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014346P 2020-04-23 2020-04-23
US63/014,346 2020-04-23
PCT/US2021/028726 WO2021216936A1 (en) 2020-04-23 2021-04-22 Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Publications (2)

Publication Number Publication Date
JP2023524912A true JP2023524912A (ja) 2023-06-13
JP2023524912A5 JP2023524912A5 (enExample) 2024-05-01

Family

ID=78221459

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509462A Pending JP2023524912A (ja) 2020-04-23 2021-04-22 ４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用

Country Status (8)

Country Link
US (2) US12208112B2 (enExample)
EP (1) EP4138843A4 (enExample)
JP (1) JP2023524912A (enExample)
KR (1) KR20230004768A (enExample)
CN (1) CN115768432A (enExample)
AU (1) AU2021260964A1 (enExample)
CA (1) CA3176543A1 (enExample)
WO (1) WO2021216936A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
KR20240139581A (ko) * 2023-03-14 2024-09-23 주식회사 피노바이오 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형
CN117187391B (zh) * 2023-09-15 2025-03-18 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用
KR20250067704A (ko) * 2023-11-08 2025-05-15 한국생명공학연구원 4'-티오-5-아자-2'-디옥시사이티딘을 포함하는 간질환의 개선, 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
CA2338415C (en) 1998-07-23 2006-10-10 Southern Research Institute Preparation of thioarabinofuranosyl compounds and use thereof
WO2004018494A1 (ja) 2002-08-22 2004-03-04 Geneticlab Co., Ltd. ４’−チオヌクレオチド
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN103951583B (zh) 2006-12-06 2016-01-06 科内图斯医药公司 一种抑制剂的结晶形式
PL3692983T3 (pl) 2008-05-15 2021-12-27 Celgene Corporation Doustne formulacje analogów cytydyny i sposoby ich zastosowania
WO2011109383A1 (en) * 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy -4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
WO2011109012A1 (en) * 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
SG11201610551TA (en) * 2014-07-14 2017-01-27 Gilead Sciences Inc Combinations for treating cancers
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
CN109553651B (zh) 2015-04-03 2021-08-06 四川科伦博泰生物医药股份有限公司 4’-硫代核苷的新型化合物及其制备方法、药物组合物和应用
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
US10815264B2 (en) 2015-05-27 2020-10-27 Southern Research Institute Nucleotides for the treatment of cancer
EP3207932A1 (en) * 2016-02-19 2017-08-23 Universität Stuttgart Dna methyltransferase inhibitors for rett syndrome therapy
EP3527226A4 (en) * 2016-10-17 2020-06-17 Daiichi Sankyo Company, Limited COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR
EP3746452B1 (en) * 2018-02-01 2023-09-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides
EP3856754A1 (en) * 2018-09-25 2021-08-04 The United States of America, as represented by the Secretary, Department of Health and Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204637A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. Vol.76, No.14, Suppl., JPN6025015872, 2016, pages 4722, ISSN: 0005710767 *
JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.37, No.15, Suppl., JPN6025015874, 2019, ISSN: 0005710769 *
MOL CANCER THER, vol. Vol.17, No.1, Suppl., JPN6025015873, 2018, pages 12, ISSN: 0005710768 *

Also Published As

Publication number Publication date
AU2021260964A1 (en) 2022-12-01
US20210330689A1 (en) 2021-10-28
CA3176543A1 (en) 2021-10-28
KR20230004768A (ko) 2023-01-06
EP4138843A1 (en) 2023-03-01
US20250082662A1 (en) 2025-03-13
EP4138843A4 (en) 2024-07-10
US12208112B2 (en) 2025-01-28
WO2021216936A1 (en) 2021-10-28
CN115768432A (zh) 2023-03-07

Similar Documents

Publication Publication Date Title
JP2023524912A (ja) ４’－チオ－５－アザ－２’－デオキシシチジンを使用して血液がんを治療するための組成物及びその使用
DE60223670T2 (de) Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen.
EP1244456B1 (en) A pyrrolidineacetamide derivative for treatment of chronic or neuropathic pain
EP3662909A1 (en) Gamma secretase modulators for the treatment of immune system dysfunction
US7396819B2 (en) Anthelmintic formulations
JPWO2014038630A1 (ja) セシウム排泄剤、有害金属排泄剤、飲食品、飼料および医薬品
US20140274937A1 (en) Methods of treating hematologic cancers
BG107038A (bg) Гелен паразитициден състав
EP2015743A2 (de) Glutadon
CN101528251B (zh) 用于预防和治疗糖尿病性周围神经病变的含有g-csf的治疗剂
Shaw Suspected infection in children with cancer
RU2850769C1 (ru) Применение сополимера 2-метил-5-винилпиридина и n-винилпирролидона гидрохлорида для восстановления кроветворной функции у собак и кошек
CN1379676A (zh) 血浆代用品组合物
DE60215051T2 (de) Zusammensetzung und verfahren zur behandlung chronischer allograft-abstossung
EP0238207A1 (en) Bactericidal mixtures
EP1944037B1 (en) Remedy for mastitis
WO2025231221A1 (en) Long-acting injectable formulation for use in the treatment and prevention of leishmaniasis in humans and animals
EA051633B1 (ru) Фармацевтические композиции для применения для профилактики рецидивов употребления каннабиса и их применение
EP0885609A1 (en) Use of a pharmaceutical composition in the treatment of traumatic arthritis in horses
US20090163442A1 (en) Treatment of cancer with 2-deoxygalactose
CN114728004A (zh) 用于治疗恶性血液病的组合疗法
Hohenhaus How I manage chemotherapy toxicity.
HK40031928A (en) Gamma secretase modulators for the treatment of immune system dysfunction
Behm et al. 883 Chronic lymphocytic leukemia (CLL) in a child
Gear Practical update on canine lymphoma: 2. Treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250421

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251020